0001193125-26-210338
SEC filingRevenue grew 324.9% to $31.7M from a Lilly milestone, narrowing net loss 13.7% to -$94.3M and improving EPS 26.6% to -$0.91, though operating cash burn increased to -$128.5M amid clinical investments.
Operating loss improved 10.1% to -$107.2 million from -$119.3 million prior year, with operating margin at -337.8%. Net loss narrowed further by 13.7% to -$94.3 million, and diluted EPS advanced 26.6% to -$0.91 from -$1.24. These improvements stem from revenue growth outpacing expense increases in a pre-profitability phase, where R&D dominates as Beam invests in hematology and liver disease programs.
The CODM relies on net income (loss) for budgeting, forecasting, and quarterly variance analysis to allocate operating and capital resources, signaling disciplined oversight amid platform execution. Management highlights substantial future R&D increases for advancing programs through clinical stages, plus G&A growth for commercial readiness. Ongoing capital needs are flagged, as inability to raise funds would impair strategy execution in this capital-intensive biotech model.